本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗,我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示,便表示您已接受我們的網站使用條款。 關閉
NEW YORK, Jan. 6, 2025 /PRNewswire/ -- The global one-stop mother and baby brand Momcozy has unveiled its annual review video alongside a user testimonial video. In its annual review, Momcozy highlighted key achievements of 2024, showcasing its commitment to empowering mothers through innovative campaigns and partnerships. The year was marked by significant collaborations and community-focused initiatives that reinforced the brand's global presence and dedication to maternal support. Momcozy 2024 Year in Review: Capturing the Power of Comfort and Growth Empowering Events and Initiatives Throughout 2024, Momcozy launched several impactful events aimed at celebrating and supporting mothers worldwide. On International Women's Day in March, the "Cozy Mom: Her Infinite Power" campaign was introduced in collaboration with international fashion media Marie Claire. This initiative featured stories from four diverse women who encouraged others to embrace their true selves beyond societal expectations, showcasing the limitless potential of millennial mothers. In May, Momcozy championed the "Cozy Village: From Cozy Me to Cozy We" philosophy in honor of Mother's Day. In collaboration with Babylist, a trusted platform for millions of growing families, PSI (Postpartum Support International), and various community organizations, the brand emphasized the importance of community support for mothers. The message was clear: the journey of parenting requires not only individual effort but also collective understanding and assistance. Brand Ambassadors and Advocacy In July, Momcozy proudly announced its partnership with Nada Hafez, a 2024 Paris Olympics athlete and mother, as a brand ambassador. Hafez embodies the spirit of embracing comfort as strength both in life's daily challenges and competitive sports arenas. World Breastfeeding Week in August was marked by "Breaking Barriers: Real Support for Breastfeeding Journeys." Collaborating with international breastfeeding organizations and healthcare providers, Momcozy focused on raising awareness about breastfeeding health while addressing unique needs through practical actions. September's Brand Day event, "Cozy Evolution: Together We Grow," redefined Momcozy's mission during New York Fashion Week. The event showcased a pop-up 'Momcozy Lounge,' where over 100 fashion industry leaders, including actresses Caity Lotz and Danielle Panabaker, gathered to discuss the diverse facets of modern motherhood. As the year drew to a close in December, Momcozy partnered with supermodel and mother Iskra Lawrence for the "Cozy Holiday: Joy for All, Love for You" campaign. This initiative encourages mothers globally to enjoy peaceful moments during the busy holiday season. Annual Highlights and Future Outlook In 2024, Momcozy has significantly broadened its global strategy, reaching over 4.5 million mothers worldwide and establishing a vast sales network across numerous countries. By consistently innovating within the maternity and baby industry, Momcozy remains dedicated to genuinely supporting all mothers. Throughout the year, it has redefined "comfort" not just as a product experience but as a symbol of strength and growth. Looking forward, Momcozy is committed to supporting every mother, creating more moments of warmth and innovation, and exploring new possibilities. About Momcozy Since 2018, Momcozy has been bringing the best in comfort to mothers with wearable breast pumps, nursing bras, and other mom care products, consistently holding the top position in relevant Amazon categories. Endorsed by over 4 million mothers in over 60 countries, Momcozy offers a range of comprehensive products on multiple platforms, such as Amazon, Babylist and Boots. With continuous innovation and a commitment to creating cozy designs born from love, Momcozy is growing in reach and impact to make moms' lives easier around the world. For more information, visit https://momcozy.com. Contact: pr@momcozy.com
Women pro golfers in top 100 among competitors in 2nd annual tournament Defending champion Haruka Kawasaki of Japan sets sights on back-to-back titles Comeback in Taiwan for former World No. 1 Jiyai Shin of South Korea Foxconn-sponsored Chia-Yen Wu, hometown favorite, spotlighted for 2nd year TAIPEI, Jan. 3, 2025 /PRNewswire/ -- The LPGA of Taiwan (TLPGA), in collaboration with title sponsor Hon Hai Technology Group (Foxconn), is thrilled to announce the 2025 Foxconn TLPGA Players Championship. In its second edition, top women pro golfers will compete for a record-breaking total purse of US$1.5 million, marking a 50% increase from last year and setting a new benchmark for the TLPGA Tour. The multi-day tournament will take place February 27 to March 2 at the Orient Golf & Country Club in Taiwan, where the event was inaugurated in 2024. For the first time, the TLPGA-sanctioned tournament will feature international live broadcast coverage, airing in Japan on Sky A, alongside VL Sports and Sportcast Sports in Taiwan. World-Class Competition The 2025 Foxconn TLPGA Players Championship sets itself apart with its exceptional ranking points, substantial prize money, and elite sportsmanship. Foxconn, the world's largest electronics manufacturing service provider and as the title sponsor, is honored to drive the TLPGA Tour's international presence and competitive growth. Aim High. Swing Brilliantly. The 2025 Foxconn TLPGA Players Championship has attracted over 140 international players since registration opened in December 2024, showcasing the tournament's growing prestige. Leading the field are defending champion Haruka Kawasaki of Japan, and last year's runner-up Yu-Sang Hou of Taiwan. Foxconn-sponsored rising star Chia-Yen Wu, the 20-year-old currently ranked among the top three in Taiwan, will compete for the second year. Adding to the excitement, former World No. 1 Jiyai Shin of South Korea will make her highly anticipated return to Taiwan after seven years, entering as a top contender following her recent triumph at the ISPS Handa Australian Open. This year's match is set to feature over ten elite players ranked among the world's top 100. Following the impressive performances by Japanese players last year, the 2025 Foxconn TLPGA Players Championship will see more than 15 players from the JLPGA Tour competing for the championship trophy. The final player roster will be announced on 17 January 2025. The 2025 Foxconn TLPGA Players Championship features a 50% increase in the total purse, reaching a record US$1.5 million, the highest in the history of the TLPGA-sanctioned Tour. The tournament returns to the Orient Golf & Country Club for the second year. About TLPGA here. About Foxconn here.
NASSAU, Bahamas, Jan. 2, 2025 /PRNewswire/ -- On December 31, 2024, the "Menstrual Equity Project", jointly initiated by KuCoin, Global CSR Foundation, and the American Medical Women's Association (AMWA), has made new progress. The second batch of aid supplies has been successfully shipped to the Bahamas, providing urgently needed sanitary products for 4,000 local women and effectively improving their quality of life. The "Menstrual Equity Project" aims to offer sustainable menstrual hygiene solutions to marginalized women and girls, aligning with the United Nations' Sustainable Development Goals (SDGs). As the oldest multi-specialty medical organization promoting women's advancement in the medical field and improving women's health, AMWA's mission is in perfect alignment with KuCoin's commitment to social responsibility. With the support of the Office of the First Lady of Commonwealth of Bahamas H. E. Ann Marie Davis, this round of donated materials focuses on disposable menstrual pads. This decision reflects the local challenges of water scarcity and high washing costs, while also providing essential emergency supplies for women during natural disasters such as hurricanes and typhoons. Since KuCoin made a firm commitment to social welfare initiatives during the "KuCoin Green Future Gala" at the 28th United Nations Climate Change Conference (COP28) in 2023, the company has actively fulfilled its corporate social responsibilities. The "Menstrual Equity Project" has become a key initiative under this commitment. In March 2024, the project's first phase was implemented, distributing 1,000 menstrual kits—each containing 10 sanitary pads and 2 menstrual cups—to Suriname, St. Jude Children's Research Hospital, and domestic violence shelters in New York and California. The smooth delivery of the second batch of supplies to the Bahamas will benefit 4,000 women. Jing Zhao Cesarone, President of Global CSR Foundation, commented: "KuCoin has set a remarkable example in addressing period poverty in underserved regions, demonstrating its enthusiasm and dedication to social responsibility." Nancy Cheung, KuCoin's Chief Sustainability Officer (CSO), emphasized: "As a global leader in the digital economy, KuCoin is committed to advancing the UN's Sustainable Development Goals (SDGs). Looking ahead, we will continue to focus on key areas such as climate change, health, and education, driving more philanthropic initiatives to fruition. We also plan to expand the scope of the 'Menstrual Equity Project,' collaborating with more international organizations to improve women's living conditions and contribute to global sustainable development." About KuCoin Founded in 2017, KuCoin is one of the pioneering and most globally recognized technology platforms supporting digital economies, built on a robust foundation of cutting-edge blockchain infrastructure, liquidity solutions, and an exceptional user experience. With a connected user base exceeding 37 million worldwide, KuCoin offers comprehensive digital asset solutions across wallets, trading, wealth management, payments, research, ventures, and AI-powered bots. KuCoin has garnered accolades such as "Best Crypto Apps & Exchanges" by Forbes and has been recognized among the "Top 50 Global Unicorns" by Hurun in 2024. These recognitions reflect its commitment to user-centric principles and core values, which include integrity, accountability, collaboration, and a relentless pursuit of excellence.
SUZHOU, China, Dec. 27, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to initiate a Phase III clinical study (study number: JSKN003-306). The study aims to compare the efficacy of JSKN003 versus investigator-selected chemotherapy for the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. Ovarian cancer (OC) ranks as the third most common gynecologic malignancy in China and continues to show a rising incidence, with the highest mortality rate among all malignant gynecologic tumors. The standard treatment regimens recommended by authoritative guidelines both domestically and internationally include surgery combined with platinum-based chemotherapy and targeted therapy maintenance. However, about 70% of OC cases recur after treatment and progress to platinum-resistant ovarian cancer (PROC), leaving patients with limited effective treatment options and poor prognosis. The 2024 NCCN guideline recommend non-platinum cytotoxic drugs and targeted monotherapy as the preferred treatment option for patients with PROC. Previous studies have shown that the objective response rate (ORR) of PROC treated with non-platinum chemotherapy alone is only 4% to 13%, while the ORR for non-platinum chemotherapy combined with targeted therapy is merely 10% to 30%, highlighting an urgent need for new treatment options. JSKN003 is an anti-HER2 bispecific ADC, which is developed inhouse with Alphamab's proprietary Glycan-specific conjugation platform. Multiple clinical studies of JSKN003 are currently being conducted in Australia and China. Clinical research results have demonstrated favorable tolerability and safety profile, with promising efficacy of JSKN003 in heavily pretreated patients with advanced solid tumors. Data from two Phase I clinical studies of JSKN003 for the treatment of PROC presented at the 2024 European Society for Medical Oncology (ESMO) Congress indicated that JSKN003 monotherapy showed promising efficacy signals in patients with advanced PROC, and the efficacy was observed across patients with or without HER2 expression, prior bevacizumab treatment, prior PARP inhibitor treatment, and whether they were primary platinum-resistant. JSKN003-306 is a randomized, open-label, parallel-controlled, multi-center Phase III clinical study for the all-comer population with platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer who have received 1-4 lines of prior treatment. The study aims to compare the efficacy and safety of JSKN003 versus investigator-selected chemotherapy in this patient population. About JSKN003 JSKN003 is an anti-HER2 bispecific antibody-drug conjugate (bis-ADC), which is developed inhouse with Alphamab's proprietary Glycan-specific conjugation platform. JSKN003 can bind HER2 on the surface of tumor cells and release topoisomerase I inhibitors (TOPIi) through cellular endocytosis, thereby exert anti-tumor effects. Compared with its ADC counterparts, JSKN003 demonstrated better serum stability and stronger bystander effect, which effectively expands the therapeutic window. Multiple clinical studies at various stages of JSKN003 are currently being conducted in China and Australia. Clinical research results have demonstrated favorable tolerability and safety profile, with promising efficacy of JSKN003 in heavily pretreated patients with advanced solid tumors, especially in patients with HER2-expressing breast cancer, platinum-resistant ovarian cancer (PROC) or high HER2-expressing solid tumors. In September 2024, the Company entered a licensing agreement with JMT-Bio Technology Co., Ltd. ("JMT-Bio"), a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (stock code: 1093.HK), pursuant to which, JMT-Bio was granted the exclusive license and sublicense rights to develop, sell, offer for sale and commercialize JSKN003, for the treatment of tumor-related indications (the "Field") in mainland China (excluding Hong Kong, Macau or Taiwan) (the "Territory") and become the sole marketing authorization holder for JSKN003 for the Field in the Territory. Alphamab retains the sole right to supply JSKN003. About Alphamab Oncology Alphamab Oncology is a leading biopharmaceutical company committed to the development, manufacturing, and commercialization of cutting-edge biotherapeutics for the treatment of cancer. On December 12, 2019, the company was successfully listed on the Main Board of the Hong Kong Stock Exchange, trading under the stock code 9966. Our integrated platform seamlessly combines research, development, and manufacturing capabilities for biologics. We take pride in our extensive intellectual property portfolio, which encompasses protein/antibody engineering, antibody screening, and multi-module/multi-functional antibody modification. Distinguished by a globally competitive pipeline, Alphamab Oncology specializes in antibody-drug conjugation (ADC), single domain antibody, and bispecific antibodies. Notably, Envafolimab, the world's first subcutaneously injectable PD-L1 inhibitor, was approved by Chinese authorities in 2021, making a significant breakthrough in the convenience and accessibility of cancer treatment. Three assets are currently undergoing Phase III or pivotal clinical trials, and several other bispecific ADC new drug candidates are in early clinical stage. Multiple strategic collaborations based on innovative products or technology platforms have been established with partners such as CSPC, Arrivent, and Glenmark. Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is dedicated to the development of safe, effective and affordable drugs, leveraging a global competitive edge.
SHAH ALAM, Malaysia, Dec. 30, 2024 /PRNewswire/ -- While gender parity has seen progress in recent years, the women's health gap remains significant. Women, despite comprising half of the global labor force[1], often face under-diagnosis and under-representation in healthcare research. Biotropics Malaysia is addressing this disparity by advancing clinical studies led by women, focused on health areas that have been drawn up as top priority to close the women's health gap. Biotropics Malaysia offers clinically researched botanical ingredients for women such as SLP+®, Nu-Femme®, Physta® and BioKesum®. 1.Cardiovascular Health Cardiovascular disease (CVD) is the leading cause of death in women, with risks increasing after menopause due to hormonal changes. Biotropics' Nu-Femme® and SLP+® have been clinically validated[2] to support cardiovascular health, showing improvements in lipid profiles and reductions in 8-isoprostane, a marker of CVD. These ingredients are derived from Kacip Fatimah (Labisia pumila), a traditional Malaysian herb known for supporting feminine vitality. 2. Menstrual & Menopausal Health Natural solutions for menstrual and menopausal health are increasingly sought after by women for mental clarity, emotional stability, physical health and overall well-being. Clinical studies[3] revealed that daily supplementation with SLP+® (200-400mg) enhances overall quality of life, while Nu-Femme® (500mg) reduces severe hot flashes by 73%, joint pain by 68%, and improves vitality by 21%. Biomarker studies further show that Nu-Femme® regulates hormonal imbalances by reducing FSH and LH levels (normally elevated in women experiencing estrogen decline during menopause) and supporting healthy testosterone and estradiol levels. 3. Brain Health For women with 'brain fog' or menopausal disturbance affecting mood and negative feeling, BioKesum® (persicaria minor) offers a comprehensive approach, targeting multiple aspects of mental, mood & cognitive wellness. 500 mg daily showed improvement in cognitive flexibility, executive function and IQ performance, positive shifts in brain markers and reduction in tension, depression and anger[4]. Looking ahead, Biotropics Malaysia is excited to launch Physta® Tongkat Ali for women's health in 2025. Visit us at the Functional Food for Wellness Summit 2025 in Bangkok (Booth A5) for insights into women's health and our innovations. For details, contact marketing@biotropicsmalaysia.com or visit www.biotropicsmalaysia.com. [1] Our World in Data, March 2024. "Women's Employment - How does women's labor force participation differ across countries? How has it changed over time? What is behind these differences and changes?". https://ourworldindata.org/female-labor-supply [2] Mohd Noor, N., et. al. 2014. Efficacy and Safety of Labisia pumila var alata Water Extract Among Pre- and Postmenopausal Women. Journal of Medicinal Food: 17(8), pp. 1-10 [3] Chinnappan, et. al, 2020. Efficacy of Labisia pumila and Eurycoma longifolia standardized extracts on hot flushes, quality of life, hormone and lipid profile of peri-menopausal and menopausal women: randomized, placebo-controlled study. Food & Nutrition Research 2020: 10.29219/fnr.v64.3665 [4] Lau, H., Shahar, S., Mohamad, M., Rajab, N. F., Yahya, H. M., Che Din, N. and Abdul Hamid, H., 2020. The effects of six months Persicaria minor extract supplement among older adults with mild cognitive impairment: a double-blinded, randomized, placebo-controlled trial. BMB Complementary Medicine and Therapies 20:315.
NEW YORK, Dec. 26, 2024 /PRNewswire/ -- The global one-stop mother and baby brand Momcozy is thrilled to announce the winners of the "Love in Action" Charity Contest, a pivotal component of its holiday campaign. This initiative is designed to recognize and support charities that align with Momcozy's mission of prioritizing comfort, health, and wellbeing for mothers. The contest has successfully awarded a total of $30,000 to three outstanding organizations dedicated to enhancing maternal and family wellbeing. In this Charity Contest Momcozy received 62 nominations and 4,981 votes were cast. Momcozy Announces “Love in Action” Charity Contest Winners, Highlighting Power of Collective Action The first-place grant of $15,000 has been awarded to Mamas for Mamas, an organization that provides poverty relief and support to mothers and children to make sure no one is left behind. Shannon Christensen, Founder and National Director of Mamas for Mamas, said, "This contest was a beautiful example of how a simple idea can unite a community. Partnering with a brand like Momcozy, which values meaningful change, was truly inspiring. It showed that when we work together, we can create a ripple effect of compassion that touches lives far and wide." The second-place recipient, Let There Be Mom, received a $10,000 grant. The organization helps preserve the legacies of parents with life-threatening illnesses, ensuring their young children always have a way to learn about and remember them. "It is evident that Momcozy shares a deep passion for supporting mothers and empowering organizations that assist moms in crisis," said Kipra Anderson, Founder & Executive Director of Let There Be Mom. The third-place award of $5,000 was granted to MMHLA (Maternal Mental Health Leadership Alliance), a nonprofit improving maternal mental health through national policy, health equity, and education. Adrienne Griffen, Executive Director of MMHLA shared, "This generous grant funding and nationwide recognition boosts MMHLA's capacity to push for policies and programs to support mental health care during pregnancy and postpartum. We are so grateful to Momcozy for their leadership and commitment to improve maternal mental health." The "Love in Action" Charity Contest involved the community in selecting charities that support mothers. Nominations were open from December 3-9, after which a shortlist was created based on impact, mission, and alignment with Momcozy's values. From December 16-20, the community voted daily for the charity to receive a grant. This community-driven approach not only highlighted the importance of collective involvement but also ensured that the selected charities truly resonated with the values of comfort, health, wellbeing and putting moms first. The contest is a key element of Momcozy's "Joy for All, Love for You" campaign, which emphasizes the importance of spreading joy and love during the holiday season. By aligning the contest with this campaign, Momcozy reinforces its commitment to supporting mothers and families through initiatives that are driven by community engagement. Athena, CEO of Momcozy highlighted the significance of community involvement in supporting maternal wellbeing, stating, "Community engagement is at the heart of our mission. By working together, we can make a meaningful impact on the lives of mothers and families. This contest is a testament to the power of collective action, and we are proud to support these incredible charities. We encourage continued community involvement and support for the winning organizations as they continue their vital work." The "Love in Action" Charity Contest not only celebrates the spirit of giving but also underscores the importance of supporting those who dedicate their efforts to enhancing the lives of mothers and families. Through this initiative, Momoczoy reaffirms its dedication to fostering a community that prioritizes the wellbeing of mothers, ensuring that they receive the support and resources they need to thrive. About Momcozy Since 2018, Momcozy has been bringing the best in comfort to mothers with wearable breast pumps, nursing bras, and other mom care products, consistently holding the top position in relevant Amazon categories. Endorsed by over 4 million mothers in over 60 countries, Momcozy offers a range of comprehensive products on multiple platforms, such as Amazon, Babylist and Boots. With continuous innovation and a commitment to creating cozy designs born from love, Momcozy is growing in reach and impact to make moms' lives easier around the world. For more information, visit https://momcozy.com. Contact: pr@momcozy.com
A12 藝術空間
Women-related news
請先登入後才能發佈新聞。
還不是會員嗎?立即 加入台灣產經新聞網會員 ,使用免費新聞發佈服務。 (服務項目) (投稿規範)